The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2025 | Deciding the best treatment strategy for borderline resectable NSCLC
Isabelle Schmitt-Opitz, MD, University Hospital Zurich, Zurich, Switzerland, comments on the challenges of managing borderline resectable non-small cell lung cancer (NSCLC) and N2 subcategories in tumor boards, emphasizing the need for a case-by-case approach that relies on surgical and center expertise. Clinicians should remaining open to the potential benefits of induction immunochemotherapy approaches followed by surgery for patients. This interview took place at the European Lung Cancer Congress (ELCC) 2025 in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
